Target type: cellularcomponent
An integrin complex that comprises one alpha1 subunit and one beta1 subunit. [PMID:12297042]
The integrin alpha1-beta1 complex, also known as VLA-1, is a heterodimeric transmembrane receptor that plays a crucial role in cell adhesion, migration, and signaling. It is composed of two subunits: the alpha1 subunit (CD49a) and the beta1 subunit (CD29).
The alpha1 subunit contains an extracellular domain responsible for binding to collagen, a major component of the extracellular matrix. This domain consists of a series of repeated motifs known as von Willebrand factor type A (VWA) domains. The beta1 subunit contains a cytoplasmic domain that interacts with intracellular signaling molecules, mediating communication between the extracellular environment and the cell's interior.
The integrin alpha1-beta1 complex is typically localized to focal adhesions, specialized structures that anchor cells to the ECM. These adhesions are dynamic and involve a complex interplay of proteins, including actin filaments, talin, and vinculin. When integrins bind to collagen, they trigger intracellular signaling pathways that regulate cell behavior, such as cell spreading, migration, and differentiation.
In addition to its role in cell adhesion, integrin alpha1-beta1 complex is also involved in a variety of other cellular processes, including:
* **Cell proliferation:** Integrin alpha1-beta1 complex can stimulate cell growth and proliferation by activating signaling pathways that promote cell cycle progression.
* **Cell survival:** This integrin complex can protect cells from apoptosis (programmed cell death) by activating signaling pathways that promote cell survival.
* **Tissue repair:** Integrin alpha1-beta1 complex is essential for wound healing and tissue regeneration.
In summary, the integrin alpha1-beta1 complex is a vital transmembrane receptor that plays a multifaceted role in cell adhesion, signaling, and a variety of other cellular processes. Its interaction with collagen is critical for regulating cell behavior, ensuring proper tissue development and function.'
"
| Protein | Definition | Taxonomy |
|---|---|---|
| Integrin beta-1 | An integrin beta-1 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P05556] | Homo sapiens (human) |
| Compound | Definition | Classes | Roles |
|---|---|---|---|
| haloperidol | haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety. Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) | aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol | antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist |
| 1,3-ditolylguanidine | 1,3-ditolylguanidine: structure given in first source; a selective ligand for the sigma binding sites in the brain | toluenes | |
| tirofiban | tirofiban : A member of the class of piperidines that is L-tyrosine in which a hydrogen attached to the amino group is replaced by a butylsulfonyl group and in which the hydrogen attached to the phenolic hydroxy group is replaced by a 4-(piperidin-4-yl)butyl group. Tirofiban: Tyrosine analog and PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX antagonist that inhibits PLATELET AGGREGATION and is used in the treatment of ACUTE CORONARY SYNDROME. | L-tyrosine derivative; piperidines; sulfonamide | anticoagulant; fibrin modulating drug; platelet glycoprotein-IIb/IIIa receptor antagonist |
| arginyl-glycyl-aspartic acid | arginyl-glycyl-aspartic acid: amino acid sequence of basic unit of widespread cellular recognition system | oligopeptide | |
| arginyl-glycyl-aspartyl-serine | arginyl-glycyl-aspartyl-serine: corresponds to cell attachment site of fibronectin; located near carboxyl-terminal region of alpha-chain of fibrinogen; inhibits platelet aggregation & fibrinogen binding to activated platelets | ||
| glycyl-arginyl-glycyl-aspartyl-serine | glycyl-arginyl-glycyl-aspartyl-serine: synthetic peptide from fibronectins; inhibits experimental metastasis of murine melanoma cells | ||
| d-arg-gly-asp-trp | arginyl-glycyl-aspartyl-tryptophan: a synthetic RGD-containing peptide | ||
| l 738167 | L 738167: structure in first source | ||
| cilengitide | Cilengitide: an alphaVbeta3 integrin antagonist that paralyzes cancer cells | oligopeptide | |
| l 734217 | L 734217: fibrinogen receptor antagonist; structure given in first source | ||
| cyclopamine | piperidines | glioma-associated oncogene inhibitor | |
| arginyl-glycyl-aspartyl-phenylalanine | |||
| cyclic(arg-gly-asp-d-phe-val) | |||
| mk-0429 | |||
| mocetinostat | mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11). mocetinostat: undergoing phase II clinical trials for treatment of cancer | aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline | antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent |
| tr 14035 | N-(2,6-dichlorobenzoyl)-4-(2',6'-bismethoxyphenyl)phenylalanine: TR-14035 is the (L)-isomer; an antagonist of both alpha4beta1 and beta7 integrins; structure in first source | ||
| bio 1211 | BIO 1211: integrin alpha4beta1 inhibitor; structure in first source |